962 related articles for article (PubMed ID: 21813548)
41. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
[TBL] [Abstract][Full Text] [Related]
42. Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis.
Heiberg T; Kvien TK; Mowinckel P; Aletaha D; Smolen JS; Hagen KB
Ann Rheum Dis; 2008 Jul; 67(7):967-71. PubMed ID: 17965118
[TBL] [Abstract][Full Text] [Related]
43. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
44. Continual Maintenance of Remission Defined by the ACR/EULAR Criteria in Daily Practice Leads to Better Functional Outcomes in Patients with Rheumatoid Arthritis.
Shidara K; Nakajima A; Inoue E; Hoshi D; Sugimoto N; Seto Y; Tanaka E; Momohara S; Taniguchi A; Yamanaka H
J Rheumatol; 2017 Feb; 44(2):147-153. PubMed ID: 27909083
[TBL] [Abstract][Full Text] [Related]
45. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
[TBL] [Abstract][Full Text] [Related]
46. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
Pincus T; Furer V; Keystone E; Yazici Y; Bergman MJ; Luijtens K
Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1142-9. PubMed ID: 21485024
[TBL] [Abstract][Full Text] [Related]
47. Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in the forefeet on outcome.
van Tuyl LH; Britsemmer K; Wells GA; Smolen JS; Zhang B; Funovits J; van Schaardenburg D; Felson D; Boers M
Ann Rheum Dis; 2012 Jan; 71(1):33-7. PubMed ID: 21953347
[TBL] [Abstract][Full Text] [Related]
48. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.
Felson DT; Smolen JS; Wells G; Zhang B; van Tuyl LH; Funovits J; Aletaha D; Allaart CF; Bathon J; Bombardieri S; Brooks P; Brown A; Matucci-Cerinic M; Choi H; Combe B; de Wit M; Dougados M; Emery P; Furst D; Gomez-Reino J; Hawker G; Keystone E; Khanna D; Kirwan J; Kvien TK; Landewé R; Listing J; Michaud K; Martin-Mola E; Montie P; Pincus T; Richards P; Siegel JN; Simon LS; Sokka T; Strand V; Tugwell P; Tyndall A; van der Heijde D; Verstappen S; White B; Wolfe F; Zink A; Boers M
Ann Rheum Dis; 2011 Mar; 70(3):404-13. PubMed ID: 21292833
[TBL] [Abstract][Full Text] [Related]
49. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.
Schoels M; Alasti F; Smolen JS; Aletaha D
Arthritis Res Ther; 2017 Jul; 19(1):155. PubMed ID: 28676129
[TBL] [Abstract][Full Text] [Related]
51. Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.
Mack ME; Hsia E; Aletaha D
Arthritis Rheumatol; 2017 Mar; 69(3):518-528. PubMed ID: 27696724
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort.
Khanna D; Oh M; Furst DE; Ranganath V; Gold RH; Sharp JT; Park GS; Keystone EC; Paulus HE;
Arthritis Rheum; 2007 Apr; 57(3):440-7. PubMed ID: 17394230
[TBL] [Abstract][Full Text] [Related]
53. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
[TBL] [Abstract][Full Text] [Related]
54. ACR/EULAR Definitions of Remission Are Associated with Lower Residual Inflammatory Activity Compared with DAS28 Remission on Hand MRI in Rheumatoid Arthritis.
Lisbona MP; Solano A; Ares J; Almirall M; Salman-Monte TC; Maymó J
J Rheumatol; 2016 Sep; 43(9):1631-6. PubMed ID: 27370881
[TBL] [Abstract][Full Text] [Related]
55. Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial.
Sanmartí R; Marsal S; Valverde J; Casado E; Lafuente R; Kashiwagi N; Rodriguez-Cros JR; Erra A; Reina D; Gratacós J
Rheumatology (Oxford); 2005 Sep; 44(9):1140-4. PubMed ID: 15927997
[TBL] [Abstract][Full Text] [Related]
56. The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study.
van den Broek M; Dirven L; Klarenbeek NB; Molenaar TH; Han KH; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
Ann Rheum Dis; 2012 Feb; 71(2):245-8. PubMed ID: 22110122
[TBL] [Abstract][Full Text] [Related]
57. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study.
Lee YC; Cui J; Lu B; Frits ML; Iannaccone CK; Shadick NA; Weinblatt ME; Solomon DH
Arthritis Res Ther; 2011 Jun; 13(3):R83. PubMed ID: 21651807
[TBL] [Abstract][Full Text] [Related]
58. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
[TBL] [Abstract][Full Text] [Related]
59. Smoking at onset of rheumatoid arthritis (RA) and its effect on disease activity and functional status: experiences from BARFOT, a long-term observational study on early RA.
Söderlin MK; Petersson IF; Bergman S; Svensson B;
Scand J Rheumatol; 2011; 40(4):249-55. PubMed ID: 21338325
[TBL] [Abstract][Full Text] [Related]
60. Treatment decisions and related costs differ significantly depending on the choice of a disease activity index in RA, according to 1987 and 2010 classification criteria.
de Jong PH; Hazes JM; van Zeben D; van der Lubbe PA; de Jager MH; de Sonnaville PB; Luime JJ; Weel AE
Rheumatology (Oxford); 2012 Jul; 51(7):1269-77. PubMed ID: 22378716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
